A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Recruiting · Phase 3 · NCT06672939
Conditions: Obesity, Overweight
At a glance
- Research payments reported, 2025
- $1.1M
- U.S. investigators named
- 13
- Sites paid
- 11
- Planned or actual enrollment
- 150
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Placebo (drug)
- Dates
- Started 2024-11-18; completion 2031-01
- Results posted
- Not yet
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months. Participants who have completed the primary PW01 study (including the 4-week safety follow-up period) will have the opportunity to receive an additional 156 weeks of treatment with orforglipron as well as continuing the lifestyle intervention.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.1M in research payments for this study in 2025 (18 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Carey Chronis, M.D. Pediatrics · Ventura, CA
- David M. Radin, MD Internal Medicine · Stamford, CT
- Jibran E. Atwi, MD Allergy & Immunology · Lafayette, LA
- Delores C. Dotson, MD Family Medicine · Hazelwood, MO
- Paul G. Matherne, MD Family Medicine · Gulfport, MS
- Kathryn J. Lucas, MD Endocrinology & Diabetes · Morehead City, NC
- Brandon J. Essink, M.D. Family Medicine · Creighton, NE
- Silva A. Arslanian, MD Specialist · Pittsburgh, PA
- Gitanjali Srivastava, M.D. Obesity Medicine · Nashville, TN
- Kashif R. Ali, M.D. Pediatrics · Houston, TX
- Vicki E. Miller, M.D. Family Medicine · Pasadena, TX
- Ifeyinwa P. Onwudiwe, MD Pediatrics · Pearland, TX
- Barbara E. Rizzardi, MD Internal Medicine · Sandy, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dynamed Clinical Research LP, DBA Dm Clinical Research $300,803
- Fomat Medical Research Inc $272,485
- Lucas Research Inc $127,297
- Sundance Clinical Research LLC $99,840
- Velocity Clinical Research Inc $87,608
- Univ of Pittsburgh Cancer Institute Cancer Srvcs $65,558
- Chemidox Advance Clinical Trials LLC $53,917
- Vanderbilt University Medical Center, TN $44,499
- Stamford Therapeutics Consortium $23,884
- New England Research Associates LLC $22,823
- $3,125
- Chemidox Clinical Trials Inc $2,700
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.